Relay Therapeutics Jumps 16% on New Clinical Data for Its Cancer Drug in Rare Disease

NEW YORK, April 3 —

Relay Therapeutics (RLAY) surged 16% to $12.54 after announcing clinical data on its lead drug in a brand-new disease area.

What Actually Happened

Relay is taking Zovegalisib, a PI3Kα inhibitor originally developed for cancer, and testing it in vascular anomalies. These are rare conditions where blood vessels form abnormally, often driven by the same PI3Kα mutations that fuel certain tumors. The biology makes sense: same target, different tissue, potentially a whole second franchise.

The ISSVA World Congress presentation marks the first time Relay has shown clinical data outside oncology. That matters because it transforms Zovegalisib from a single-indication cancer drug into a platform asset. One molecule, two markets. The stock moved because investors suddenly have to price in optionality they weren't modeling before.

The Catch

A 16% move on "initial clinical data" is the market buying the trailer, not the movie. Vascular anomalies are a small patient population. Even if Zovegalisib works perfectly here, this indication alone won't justify the company's market cap. The real question is whether this data de-risks the larger oncology program, and that's a stretch. Efficacy in rare vascular conditions doesn't guarantee efficacy in solid tumors with different microenvironments and resistance mechanisms.

There's also a precedent problem. PI3K inhibitors have a checkered history in oncology. Novartis pulled Piqray's EU approval. Gilead discontinued Zydelig development. The class works, but side effects (hyperglycemia, rash, colitis) have killed multiple programs. Relay needs to show Zovegalisib is cleaner than its predecessors, and "initial data" presentations rarely include the long-term safety follow-up that matters most.

Bottom Line

This is a legitimately interesting catalyst for a stock that needed one. At $15mn TTM revenue and a negative forward P/E, Relay is priced as a binary bet on Zovegalisib's clinical success. The vascular anomalies data adds a second way to win, which matters when your entire valuation depends on one molecule. But the 16% pop already prices in a lot of optimism for a dataset nobody has seen yet.

Watch the ISSVA presentation for two things: objective response rates and the safety profile, specifically rates of hyperglycemia and GI toxicity. Those numbers will tell you whether this drug can actually compete in the PI3K space or if it joins the graveyard.

Relay Therapeutics doesn't have a full Basis Report yet. Generate your RLAY equity research report here.

Basis Report does not hold positions in securities discussed. This is not investment advice.